This is one of the cheapest and highest quality cannabis pharmaceutical stocks on the market. There's been a few months since the financing for the company to plan their next steps....we know they are looking to fine tune their drug delivery platforms and advance some of their candidate molecules into Phase I, they're also seeking big pharma partners to lead the clinical programs....any significant progress on these fronts and these prices will be a distant memory.
News 
Market Data 
Discover 
